Swapnil Vaidya, MD
Allergy · Fort Worth, TXNPI 1457575615
Payments from drug & device makers
Across 430 payments — averaging $1126.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$210K
- Arcutis Biotherapeutics, Inc.$136K
- Eli Lilly$64K
- Dermira, Inc.$15K
- Regeneron$14K
- E.r. Squibb & Sons, L.L.C.$13K
- plus $32K from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 67 | $210,482 |
| Arcutis Biotherapeutics, Inc. | 42 | $135,595 |
| Eli Lilly | 11 | $63,991 |
| Dermira, Inc. | 3 | $14,604 |
| Regeneron | 21 | $14,443 |
| E.r. Squibb & Sons, L.L.C. | 2 | $13,046 |
| Novartis | 9 | $12,358 |
| Teva Pharmaceuticals USA, Inc. | 20 | $9,939 |
| Sanofi US Services Inc. | 7 | $4,514 |
| AstraZeneca | 65 | $1,472 |
| Regeneron Healthcare Solutions, Inc. | 27 | $747 |
| Sanofi | 29 | $669 |
| Genentech USA, Inc. | 12 | $367 |
| GSK | 22 | $339 |
| Grifols USA, LLC | 10 | $224 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $201 |
| Pharming Healthcare, Inc. | 7 | $162 |
| ARS Pharmaceuticals Operations, Inc. | 13 | $157 |
| Amgen | 9 | $152 |
| Shire North American Group Inc | 7 | $142 |
| CSL Behring | 4 | $102 |
| Kaleo, Inc. | 6 | $96 |
| Biocryst US Sales Co., LLC | 3 | $77 |
| Alk-abello, Inc | 4 | $67 |
| Optinose US, Inc. | 3 | $52 |
| Phathom Pharmaceuticals, Inc. | 3 | $50 |
| Phadia US Inc. | 3 | $47 |
| Boehringer Ingelheim | 3 | $41 |
| Organon | 2 | $34 |
| Galderma Laboratories, L.p. | 2 | $31 |
| Azurity Pharmaceuticals, Inc. | 2 | $28 |
| Incyte Corporation | 1 | $28 |
| Lilly USA, LLC | 1 | $18 |
| Greer Laboratories, Inc. | 1 | $15 |
How this compares
$484,294 in reported general payments places this provider in the 95th percentile of 69 allergy providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy in Fort Worth
- John FlingFort Worth$193K
- Dalia GaliciaFort Worth$7K
- Susan BaileyFort Worth$4K
- David FuentesBoerne$14.5M
- Gary GrossDallas$3.7M
- Brian MillerGeorgetown$168K
- Dennis DilleySan Antonio$73K
- Rene LeonSouthlake$48K
- Dustin FowlerWaco$42K
- Christina HuddlestonDallas$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.